{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:45:34Z","timestamp":1792583134039,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.therap.2026.09.044","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:12:30Z","timestamp":1790377950000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Onset of vitiligo during bimekizumab treatment for psoriasis"],"prefix":"10.1016","author":[{"given":"Elodie","family":"Potereau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Babin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.09.044_bib0120","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1007\/s12325-024-02875-0","article-title":"Epidemiology and treatment patterns of patients with vitiligo: a real-world analysis","volume":"41","author":"Ramot","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.therap.2026.09.044_bib0125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.therap.2026.09.044_bib0130","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2026.09.044_bib0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2026.09.044_bib0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","article-title":"Functional specialization of interleukin-17 family members","volume":"34","author":"Iwakura","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.therap.2026.09.044_bib0145","first-page":"e208","article-title":"Interleukin-17 level in patients with vitiligo: a systematic review and meta-analysis","volume":"61","author":"Prakash","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.therap.2026.09.044_bib0150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/exd.13773","article-title":"Role of IL-17A receptor blocking in melanocyte survival: A strategic intervention against vitiligo","volume":"28","author":"Bhardwaj","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.therap.2026.09.044_bib0155","doi-asserted-by":"crossref","first-page":"e15305","DOI":"10.1111\/dth.15305","article-title":"Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.therap.2026.09.044_bib0160","doi-asserted-by":"crossref","first-page":"omz134","DOI":"10.1093\/omcr\/omz134","article-title":"Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris","volume":"2020","author":"Palazzo","year":"2020","journal-title":"Oxf Med Case Reports"},{"key":"10.1016\/j.therap.2026.09.044_bib0165","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.therap.2026.09.044_bib0170","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/fcp.12558","article-title":"Drug-induced vitiligo: a case\/non-case study in Vigibase\u00ae, the WHO pharmacovigilance database","volume":"34","author":"Anthony","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.09.044_bib0175","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40261-020-00964-w","article-title":"New-onset vitiligo during treatment with secukinumab: report of two cases and review of the literature","volume":"40","author":"Nieto-Benito","year":"2020","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.therap.2026.09.044_bib0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000510831","article-title":"Vitiligo with progressive repigmentation during secukinumab treatment in a patient with psoriatic arthritis: a case report","volume":"13","author":"Giordano","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.therap.2026.09.044_bib0185","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.5021\/ad.21.078","article-title":"Progression of pre-existing vitiligo during secukinumab treatment for psoriasis","volume":"35","author":"Kim","year":"2023","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.therap.2026.09.044_bib0190","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.therap.2022.12.004","article-title":"Secukinumab-induced vitiligo: a new case report and review of the literature","volume":"78","author":"Bouzid","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.09.044_bib0195","doi-asserted-by":"crossref","first-page":"e12852","DOI":"10.1111\/dth.12852","article-title":"Multiple paradoxical reactions during ixekizumab therapy","volume":"32","author":"Pirro","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.therap.2026.09.044_bib0200","doi-asserted-by":"crossref","first-page":"e15314","DOI":"10.1111\/dth.15314","article-title":"Vitiligo development in a patient with psoriasis vulgaris treated with ixekizumab","volume":"35","author":"Eker","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.therap.2026.09.044_bib0205","doi-asserted-by":"crossref","first-page":"e15102","DOI":"10.1111\/dth.15102","article-title":"Onset of vitiligo in a psoriasis patient on ixekizumab","volume":"34","author":"Marasca","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.therap.2026.09.044_bib0210","doi-asserted-by":"crossref","first-page":"e15872","DOI":"10.1111\/dth.15872","article-title":"Generalized vitiligo in a psoriatic patient treated with ixekizumab","volume":"35","author":"Pathmarajah","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.therap.2026.09.044_bib0215","doi-asserted-by":"crossref","first-page":"1077681","DOI":"10.3389\/fimmu.2022.1077681","article-title":"Anti-IL-17A antibody-associated de novo vitiligo: case report and review of literature","volume":"13","author":"Su","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.therap.2026.09.044_bib0220","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/ijd.ijd_204_23","article-title":"Ixekizumab-associated generalized vitiligo and pruritus in a psoriatic patient","volume":"69","author":"Jung","year":"2024","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.therap.2026.09.044_bib0225","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.therap.2026.09.044_bib0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0394-1","article-title":"Association between psoriasis and vitiligo: a systematic review and meta-analysis","volume":"20","author":"Yen","year":"2019","journal-title":"Am J Clin Dermatol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572600137X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572600137X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:26:34Z","timestamp":1792581994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572600137X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S004059572600137X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.09.044","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onset of vitiligo during bimekizumab treatment for psoriasis","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.09.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}